Lv6
2680 积分 2023-11-14 加入
Evaluation of the mycophenolate mofetil-rituximab combination in systemic sclerosis: a French retrospective multicenter study (MycRiSSc)
5个月前
已关闭
Real-world evaluation of interstitial lung disease/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan
5个月前
已完结
Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis
5个月前
已完结
Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
5个月前
已关闭
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
5个月前
已完结
Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis
5个月前
已完结
Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial
5个月前
已完结
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial
5个月前
已关闭
Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC
5个月前
已完结
Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study
5个月前
已完结
皖公网安备34019202002308
